HFA 2019: Management Of Hyperkalaemia In Patients With Heart Failure | CFR Journal

HFA 2019: Management of hyperkalaemia in patients with heart failure – Overcoming barriers to optimal renin-angiotensin-aldosterone system inhibitor therapy

 
  Topic Faculty
12:15 Welcome and introduction - Management of hyperkalaemia in patients with heart failure – Overcoming barriers to optimal renin-angiotensin-aldosterone system inhibitor therapy Faiez Zannad (Chair) 
12:20 Hyperkalaemia in patients with heart failure – Addressing the unmet medical need Mitja Lainscak 
12:35 New evidence on hyperkalaemia management in patients with heart failure, resistant hypertension and chronic kidney disease – The cardiologist’s perspective Ileana Pina
12:50 New evidence on hyperkalaemia management in patients with heart failure, resistant hypertension and chronic kidney disease – The nephrologist’s perspective Patrick Rossignol

 

The objective of the symposium is to educate on:

Recognise the importance of hyperkalaemia as a barrier to optimal renin-angiotensin-aldosterone system inhibitor therapy in patients with heart failure. Evaluate the benefits and challenges of hyperkalaemia management in patients with heart failure, resistant hypertension and chronic kidney disease. Discuss how to implement a multidisciplinary approach to improve the outcomes heart failure patients with hyperkalaemia.


Sponsored by Vifor Pharma